Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer
© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissionsoup.com..
BACKGROUND: The rate of esophagogastric cancer is rising among individuals under 50 years of age. It remains unknown whether early-onset esophagogastric cancer represents a unique entity. This study investigated the clinical and molecular characteristics of early-onset and average-onset esophagogastric cancer.
METHODS: We reviewed the Memorial Sloan Kettering Cancer Center gastric, esophageal, and gastroesophageal junction cancer database. Associations between baseline characteristics and tumor and germline molecular alterations were compared between those with early-onset and average-onset esophagogastric cancer using Fisher exact tests and the Benjamini-Hochberg method for multiple-hypothesis correction.
RESULTS: We included 1123 patients with early-onset esophagogastric cancer (n = 219; median age = 43 years [range = 18-49 years]) and average-onset esophagogastric cancer (n = 904; median age = 67 years [range = 50-94 years]) treated between 2005 and 2018. The early-onset group had more women (39% vs 28%, P = .002). Patients with early-onset esophagogastric cancer were more likely to have a gastric primary site (64% vs 44%, P < .0001). The signet ring cell and/or diffuse type was 3 times more common in the early-onset esophagogastric cancer group (31% vs 9%, P < .0001). Early-onsite tumors were more frequently genomically stable (31% vs 18%, P = .0002) and unlikely to be microsatellite instability high (2% vs 7%, P = .003). After restricting to adenocarcinoma and signet ring cell and/or diffuse type carcinomas, we observed no difference in stage (P = .40) or overall survival from stage IV diagnosis (median = 22.7 vs 22.1 months, P = .78).
CONCLUSIONS: Our study supported a preponderance of gastric primary disease sites, signet ring histology, and genomically stable molecular subtypes in early-onset esophagogastric cancer. Our findings highlight the need for further research to define the underlying pathogenesis and strategies for early detection and prevention.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:116 |
|---|---|
| Enthalten in: |
Journal of the National Cancer Institute - 116(2024), 2 vom: 08. Feb., Seite 299-308 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lumish, Melissa A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/jnci/djad186 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361963866 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361963866 | ||
| 003 | DE-627 | ||
| 005 | 20240214232808.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jnci/djad186 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM361963866 | ||
| 035 | |a (NLM)37699004 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lumish, Melissa A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: The rate of esophagogastric cancer is rising among individuals under 50 years of age. It remains unknown whether early-onset esophagogastric cancer represents a unique entity. This study investigated the clinical and molecular characteristics of early-onset and average-onset esophagogastric cancer | ||
| 520 | |a METHODS: We reviewed the Memorial Sloan Kettering Cancer Center gastric, esophageal, and gastroesophageal junction cancer database. Associations between baseline characteristics and tumor and germline molecular alterations were compared between those with early-onset and average-onset esophagogastric cancer using Fisher exact tests and the Benjamini-Hochberg method for multiple-hypothesis correction | ||
| 520 | |a RESULTS: We included 1123 patients with early-onset esophagogastric cancer (n = 219; median age = 43 years [range = 18-49 years]) and average-onset esophagogastric cancer (n = 904; median age = 67 years [range = 50-94 years]) treated between 2005 and 2018. The early-onset group had more women (39% vs 28%, P = .002). Patients with early-onset esophagogastric cancer were more likely to have a gastric primary site (64% vs 44%, P < .0001). The signet ring cell and/or diffuse type was 3 times more common in the early-onset esophagogastric cancer group (31% vs 9%, P < .0001). Early-onsite tumors were more frequently genomically stable (31% vs 18%, P = .0002) and unlikely to be microsatellite instability high (2% vs 7%, P = .003). After restricting to adenocarcinoma and signet ring cell and/or diffuse type carcinomas, we observed no difference in stage (P = .40) or overall survival from stage IV diagnosis (median = 22.7 vs 22.1 months, P = .78) | ||
| 520 | |a CONCLUSIONS: Our study supported a preponderance of gastric primary disease sites, signet ring histology, and genomically stable molecular subtypes in early-onset esophagogastric cancer. Our findings highlight the need for further research to define the underlying pathogenesis and strategies for early detection and prevention | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Walch, Henry |e verfasserin |4 aut | |
| 700 | 1 | |a Maron, Steven B |e verfasserin |4 aut | |
| 700 | 1 | |a Chatila, Walid |e verfasserin |4 aut | |
| 700 | 1 | |a Kemel, Yelena |e verfasserin |4 aut | |
| 700 | 1 | |a Maio, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Ku, Geoffrey Y |e verfasserin |4 aut | |
| 700 | 1 | |a Ilson, David H |e verfasserin |4 aut | |
| 700 | 1 | |a Won, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Joshi, Smita S |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Schattner, Mark A |e verfasserin |4 aut | |
| 700 | 1 | |a Laszkowska, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Gerdes, Hans |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, David R |e verfasserin |4 aut | |
| 700 | 1 | |a Sihag, Smita |e verfasserin |4 aut | |
| 700 | 1 | |a Coit, Daniel G |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Laura H |e verfasserin |4 aut | |
| 700 | 1 | |a Strong, Vivian E |e verfasserin |4 aut | |
| 700 | 1 | |a Molena, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Stadler, Zsofia K |e verfasserin |4 aut | |
| 700 | 1 | |a Schultz, Nikolaus |e verfasserin |4 aut | |
| 700 | 1 | |a Janjigian, Yelena Y |e verfasserin |4 aut | |
| 700 | 1 | |a Cercek, Andrea |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the National Cancer Institute |d 1945 |g 116(2024), 2 vom: 08. Feb., Seite 299-308 |w (DE-627)NLM000019747 |x 1460-2105 |7 nnns |
| 773 | 1 | 8 | |g volume:116 |g year:2024 |g number:2 |g day:08 |g month:02 |g pages:299-308 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jnci/djad186 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 116 |j 2024 |e 2 |b 08 |c 02 |h 299-308 | ||